JO2259B1 - Method for the manufacture of diazapine derivatives - Google Patents
Method for the manufacture of diazapine derivativesInfo
- Publication number
- JO2259B1 JO2259B1 JO200069A JOP20000069A JO2259B1 JO 2259 B1 JO2259 B1 JO 2259B1 JO 200069 A JO200069 A JO 200069A JO P20000069 A JOP20000069 A JO P20000069A JO 2259 B1 JO2259 B1 JO 2259B1
- Authority
- JO
- Jordan
- Prior art keywords
- diazepine derivatives
- manufacturing
- lower alkyl
- imidazo
- hydrogen
- Prior art date
Links
- 125000002576 diazepinyl group Chemical class N1N=C(C=CC=C1)* 0.000 title abstract 3
- 238000004519 manufacturing process Methods 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- IMXWNWBXKWASOM-UHFFFAOYSA-N 3h-imidazo[1,5-a][1,4]diazepine Chemical class N1=CC=CN2CN=CC2=C1 IMXWNWBXKWASOM-UHFFFAOYSA-N 0.000 abstract 1
- 102000004300 GABA-A Receptors Human genes 0.000 abstract 1
- 108090000839 GABA-A Receptors Proteins 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- JCYLWUVDHLVGER-UHFFFAOYSA-N evt-201 Chemical compound O1C(CN(C)C)=NC(C2=C3N(C4=CC=CC(Cl)=C4C(=O)N(C)C3)C=N2)=N1 JCYLWUVDHLVGER-UHFFFAOYSA-N 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical group 0.000 abstract 1
- 150000002431 hydrogen Chemical group 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 239000013067 intermediate product Substances 0.000 abstract 1
- 230000001003 psychopharmacologic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/12—1,5-Benzodiazepines; Hydrogenated 1,5-benzodiazepines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP99109514 | 1999-05-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JO2259B1 true JO2259B1 (en) | 2004-10-07 |
Family
ID=8238166
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JO200069A JO2259B1 (en) | 1999-05-12 | 2000-05-04 | Method for the manufacture of diazapine derivatives |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US6281353B1 (da) |
| EP (1) | EP1202977B1 (da) |
| JP (1) | JP3590590B2 (da) |
| KR (1) | KR100469813B1 (da) |
| CN (1) | CN101426771B (da) |
| AT (1) | ATE256669T1 (da) |
| AU (1) | AU4755500A (da) |
| CA (1) | CA2373506C (da) |
| DE (1) | DE60007324T2 (da) |
| DK (1) | DK1202977T3 (da) |
| ES (1) | ES2209880T3 (da) |
| JO (1) | JO2259B1 (da) |
| MX (1) | MXPA01011445A (da) |
| WO (1) | WO2000069835A2 (da) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090054412A1 (en) * | 2007-08-20 | 2009-02-26 | John Alan Kemp | Treatment of Sleep Disorders |
| WO2009024325A2 (en) * | 2007-08-20 | 2009-02-26 | Evotec Neurosciences Gmbh | Treatment of sleep disorders |
| CN109134471B (zh) * | 2017-06-27 | 2020-05-15 | 浙江京新药业股份有限公司 | 一种苯并二氮杂*化合物的固态形式及其制备方法和应用 |
| CN111620834B (zh) * | 2019-10-15 | 2022-05-24 | 浙江京新药业股份有限公司 | 一种苯并二氮杂䓬化合物的制备方法和中间体 |
| CN113045574B (zh) * | 2019-12-26 | 2024-06-07 | 浙江京新药业股份有限公司 | 二氮杂䓬衍生物的制备方法及其中间体 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1184175A (en) | 1981-02-27 | 1985-03-19 | Walter Hunkeler | Imidazodiazepines |
| US4352817A (en) * | 1981-02-27 | 1982-10-05 | Hoffmann-La Roche Inc. | Imidazo-diazepines and their use |
| CA1174673A (en) * | 1981-02-27 | 1984-09-18 | Walter Hunkeler | Imidazodiazepines |
| CA1185602A (en) * | 1981-02-27 | 1985-04-16 | Emilio Kyburz | Imidazodiazepines |
-
2000
- 2000-05-04 JO JO200069A patent/JO2259B1/en active
- 2000-05-05 EP EP00929501A patent/EP1202977B1/en not_active Expired - Lifetime
- 2000-05-05 MX MXPA01011445A patent/MXPA01011445A/es active IP Right Grant
- 2000-05-05 DK DK00929501T patent/DK1202977T3/da active
- 2000-05-05 AT AT00929501T patent/ATE256669T1/de active
- 2000-05-05 DE DE60007324T patent/DE60007324T2/de not_active Expired - Lifetime
- 2000-05-05 ES ES00929501T patent/ES2209880T3/es not_active Expired - Lifetime
- 2000-05-05 CN CN008074224A patent/CN101426771B/zh not_active Expired - Lifetime
- 2000-05-05 KR KR10-2001-7014340A patent/KR100469813B1/ko not_active Expired - Lifetime
- 2000-05-05 CA CA002373506A patent/CA2373506C/en not_active Expired - Lifetime
- 2000-05-05 JP JP2000618252A patent/JP3590590B2/ja not_active Expired - Lifetime
- 2000-05-05 AU AU47555/00A patent/AU4755500A/en not_active Abandoned
- 2000-05-05 WO PCT/EP2000/004033 patent/WO2000069835A2/en not_active Ceased
- 2000-05-08 US US09/566,831 patent/US6281353B1/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| DE60007324D1 (de) | 2004-01-29 |
| DE60007324T2 (de) | 2004-10-21 |
| KR20010112485A (ko) | 2001-12-20 |
| CA2373506A1 (en) | 2000-11-23 |
| ES2209880T3 (es) | 2004-07-01 |
| JP3590590B2 (ja) | 2004-11-17 |
| CA2373506C (en) | 2007-09-11 |
| ATE256669T1 (de) | 2004-01-15 |
| WO2000069835A3 (en) | 2002-03-07 |
| DK1202977T3 (da) | 2004-04-05 |
| KR100469813B1 (ko) | 2005-02-02 |
| US6281353B1 (en) | 2001-08-28 |
| JP2002544265A (ja) | 2002-12-24 |
| EP1202977B1 (en) | 2003-12-17 |
| MXPA01011445A (es) | 2002-06-04 |
| AU4755500A (en) | 2000-12-05 |
| CN101426771A (zh) | 2009-05-06 |
| WO2000069835A2 (en) | 2000-11-23 |
| CN101426771B (zh) | 2011-11-16 |
| EP1202977A2 (en) | 2002-05-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA1185602A (en) | Imidazodiazepines | |
| ATE421967T1 (de) | Nichtvernetzende pyrroloä2,1-cüä1, 4übenzodiazepine als potentielle antitumor- agentien und ihre herstellung | |
| CA1067491A (en) | Diazepine derivatives | |
| MY127939A (en) | Pharmaceutical agents for the treatment of parkinson's disease, adhd and microadenomas | |
| MA29623B1 (fr) | Derives de pyrazolo [3, 4-d] azepine comme antagonistes d'histamine h3 | |
| DE59203611D1 (de) | Verfahren zur Herstellung von 3-Amino-9,13b-dihydro-1H-dibenz-[c,f]imidazol[1,5-a]azepin-hydrochlorid. | |
| CA2184802A1 (en) | Process for manufacture of imidazo benzodiazepine derivatives | |
| JO2259B1 (en) | Method for the manufacture of diazapine derivatives | |
| CA2372040A1 (en) | Imidazodiazepine derivative | |
| MX2007004250A (es) | Derivados de imidazo[1,5-a]triazolo[1,5-d]benzodiazepina para el tratamiento de trastornos cognitivos. | |
| GR1002883B (el) | Νεα παραγωγα της 2, 3-βενζοδιαζεπινης | |
| MX2007004640A (es) | Derivados de benzodiazepina sustituidos con halogeno. | |
| BR0213177A (pt) | Derivados de 5-metóxi-8-aril-[1,2,4]triazolo[1,5-a]piridina | |
| FI71150C (fi) | Foerfarande foer framstaellning av som neuroleptiska laekemedel anvaendbara 2,4-dihydro-1,2,3-triazolo/4,5-b/ /1,5/bensodiazepinderivat | |
| ATE251162T1 (de) | Triazolo(4,5-d)pyrimidin-verbindungen | |
| HU9203325D0 (en) | Benzo-thieno(2,3-b)pyrazine-2,3(1h,4h)-dione derivatives | |
| DE69910574D1 (de) | Pyrazolo[1,5-a]triazine als crf antagonisten | |
| AP9801410A0 (en) | Indoline derivatives useful as 5-HT-2C receptor antagonists. | |
| AP1631A (en) | Polymorphs of N-methyl-N- (3- {3- [2-thienylcarbonyl] -pyrazol- [1,5-?] -pyrimidin-7-yl} phenyl) acetamide and compositions and methods related thereto. | |
| GB2425309A (en) | C2-fluoro pyrrolo[2,1-c][1,4]benzodiazepine dimers | |
| ATE469904T1 (de) | Pyren-gebundene pyrrolo(2,1-c)(1,4)benzodiazepin- derivate zur verwendung als antikrebsmittel | |
| US3717653A (en) | Triazolobenzodiazepines and their production | |
| US4001261A (en) | Process for the production of 1-[(dimethylamino)methyl]-6-phenyl-4H-imidazo[1,2-a][1,4]-benzodiazepine | |
| Walser et al. | Quinazolines and 1, 4‐benzodiazepines. XCVI. Compounds derived from benzodiazepine‐2‐acetic acid | |
| PT80746A (en) | Pyrrolo<1,2-b> <1,2,5>triazepines a process and intermediates for their preparation and their use as medicaments |